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SObjectives: The present multicenter study compared the usefulness of the solid tumor size with that of the whole
tumor size on preoperative high-resolution computed tomography for predicting pathologic high-grademalignancy
(positive lymphatic, vascular, or pleural invasion) and the prognosis of clinical stage IA lung adenocarcinoma.
Methods:We performed high-resolution computed tomography and F-18 fluorodeoxyglucose-positron emission
tomography/computed tomography before curative surgical resection in 502 patients with clinical stage IA lung
adenocarcinoma. The revised maximum standardized uptake values on F-18 fluorodeoxyglucose-positron emis-
sion tomography/computed tomography were used to correct interinstitutional discrepancies. The whole and solid
tumor sizes on high-resolution computed tomography were then analyzed in relation to surgical results.
Results: The mean whole and solid tumor size was 1.97  0.59 cm and 1.20  0.88 cm, respectively. The re-
ceiver operating characteristics area under the curve for the whole and solid tumor sizes used to identify high-
grade malignancy were 0.590 and 0.829, respectively. Multiple logistic regression analyses demonstrated solid
tumor size (P<.001) and maximum standardized uptake values of the tumor (P<.001) as independent variables
for the prediction of high-grade malignancy. Multivariate Cox analysis of disease-free survival demonstrated the
former (hazard ratio, 2.30; 95% confidence interval, 1.46-3.63; P<.001) and latter (hazard ratio, 1.08; 95%
confidence interval, 1.00-1.17; P ¼ .05) as independent prognostic factors.
Conclusions: The solid tumor size on high-resolution computed tomography andmaximum standardized uptake
values on positron emission tomography/computed tomography have greater predictive value for high-grade
malignancy and prognosis in clinical stage IA lung adenocarcinoma than that of whole tumor size. (J Thorac
Cardiovasc Surg 2012;143:607-12)Recent advances in high-resolution computed tomography
(HRCT) and the widespread application of computed to-
mography (CT) screening have enhanced the discovery of
small lung cancers, particularly adenocarcinoma.1,2 These
often contain a nonsolid component that presents as
ground glass opacity (GGO) on HRCT.2,3 Several
investigators have reported that GGO is closely associated
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The Journal of Thoracic and Cacolleagues5 reported that type A and B small peripheral ad-
enocarcinomas (localized bronchioloalveolar carcinoma
without foci of active fibroblastic proliferation) demon-
strated no lymph node metastasis and a favorable prognosis
(100% 5-year survival rate). We therefore hypothesized
that the GGO component is not related to malignancy and
prognosis, implying that only the solid component of the tu-
mor on HRCT (solid tumor size) is indicative of malignancy
and prognosis.
The purpose of the present multicenter study was to eval-
uate and compare the usefulness of the solid tumor size with
that of the whole tumor size as seen on preoperative HRCT
for determining pathologic high-grade malignancy (posi-
tive for lymphatic [LI], vascular [VI], or pleural invasion
[PI]) and the prognosis in cases of clinical stage IA lung
adenocarcinoma.
PATIENTS AND METHODS
Patients
We enrolled 502 patients with clinical T1N0M0 stage IA lung adenocar-
cinoma at 4 institutions (Hiroshima University, Kanagawa Cancer Center,
Cancer Institute Hospital, and Hyogo Cancer Center) from August 1, 2005rdiovascular Surgery c Volume 143, Number 3 607
Abbreviations and Acronyms
CI ¼ confidence interval
CT ¼ computed tomography
DFS ¼ disease-free survival
FDG-
PET
¼ F-18 fluorodeoxyglucose-positron
emission tomography
GGO ¼ ground glass opacity
HR ¼ hazard ratio
HRCT ¼ high-resolution computed tomography
LI ¼ lymphatic invasion
PI ¼ pleural invasion
SUV ¼ standardized uptake value
VI ¼ vascular invasion
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Sto December 31, 2009. HRCTand F-18 fluorodeoxyglucose-positron emis-
sion tomography/CT (FDG-PET/CT) followed by curative R0 resection
were performed for all patients, who underwent staging according to the
7th edition of the TNMclassification of malignant tumors.6 Sublobar resec-
tions (segmentectomy or wedge resection) were allowed if the tumor
mainly consisted of GGO or had no lymph node metastasis through intra-
operative assessment. The institutional review board of each institution
provided appropriate approval for the present multicenter study. They
waived the requirement of informed consent from the individual patients
for the present retrospective review of the prospective database. The data
were compiled in a Microsoft Excel 2010 file (Microsoft, Redmond, WA).
HRCT Scanning
Chest images were obtained using 16-row, multidetector CT, indepen-
dent of the subsequent FDG-PET/CT examinations. High-resolution im-
ages of the tumors were acquired using the following parameters: 120
kVp, 200 mA, 1- to 2-mm section thickness, 512 3 512 pixel resolution,
scanning time 0.5 to 1 sec, and a high spatial reconstruction algorithm
with a 20-cm field of view and mediastinal (level, 40 HU; width, 400
HU) and lung (level,600 HU; width, 1600 HU) window settings. GGO
was defined as a misty increase in lung attenuation that did not obscure
the underlying vascular markings. We defined the solid tumor size as the
maximum dimension of the solid component of the lung windows exclud-
ing GGO (Figure 1).
FDG-PET/CT Scanning
The patients were instructed to fast for more than 4 hours before intra-
venous injection of 74 to 370 MBq FDG and then made to relax for at least
1 hour before FDG-PET/CT scanning. Blood glucosewas calculated before
the tracer injection to confirm a level of less than 150 mg/dL.7 Patients with
blood glucose values of 150 mg/dL or greater were excluded from PET/CT
acquisition. The images were obtained using Discovery ST (GE Health-
care, Little Chalfont, UK), Aquiduo (Toshiba Medical Systems, Tochigi,
Japan), or Biograph Sensation16 (Siemens Healthcare, Erlangen, Ger-
many) integrated PET/CT scanners. Low-dose, unenhanced CT images
of 2- to 4-mm section thickness for attenuation correction and localization
of lesions identified by PETwere obtained from the head to the pelvic floor
of each patient using a standard protocol. Immediately after CT, PET cov-
ered the identical axial field of view for 2 to 4 minutes per table position,
depending on the condition of the patient and scanner performance. All
PET images with a 50-cm field of view were reconstructed using an itera-
tive algorithm with CT-derived attenuation correction. Variations in the
standardized uptake values (SUVs) among institutions were minimized us-
ing an anthropomorphic body phantom. A calibration factor was analyzed608 The Journal of Thoracic and Cardiovascular Surgby dividing the actual SUV by the gauged mean SUV in the phantom back-
ground to decrease interinstitutional SUV inconsistencies. The final SUV
reported in the present study is referred to as the revised maximum SUV
(maxSUV).8,9 The adjustment of the interinstitutional variability in the
SUV narrowed the range from 0.89 to 1.24 to 0.97 to 1.18 when the
maxSUV ratio was expressed as the maxSUVof each institute relative to
the maxSUVof the control institute.
Statistical Analysis
The data are presented as the numbers and percentages or mean stan-
dard deviation, unless otherwise stated. Pathologic high-grade malignancy
was defined as positive LI, VI, or PI. The receiver operating characteristic
curves of the whole and solid tumor sizes were used for the prediction of
LI, VI, or PI, high-grade malignancy (LI, VI, or PI), and lymph node metas-
tasis. We also performed multiple logistic regression analyses to determine
the independent variables related to whole tumor size, solid tumor size,
and maxSUV for the prediction of the pathologic finding of high-grade ma-
lignancy. Disease-free survival (DFS)was defined as interval from the date of
surgery until the first event (relapse or death from any cause) or the last
follow-up visit. The duration of DFS was analyzed using the Kaplan-Meier
method. Differences in DFS were assessed using the log-rank test. To assess
the potential independent effects of clinical tumor size onDFS, we performed
multivariate analyses with the Cox proportional hazards model using vari-
ables with P<.05 on the univariate analyses; P<.05 was considered statis-
tically significant. The data were statistically analyzed using the Statistical
Package for Social Sciences software, version 10.5 (SPSS, Chicago, ll).RESULTS
The characteristics of the 502 study patients are summa-
rized in Table 1. The mean follow-up period after surgery
was 19.8  12.2 months, during which disease recurred in
29 patients (5.8%). Of the 29 recurrence cases, 9 (1.8%)
were local, including mediastinal lymph node metastasis,
3 (0.6%) were local and distant, and 17 (3.4%) were dis-
tant. The mean whole tumor and solid tumor size on
HRCT was 1.97  0.59 cm and 1.20  0.88 cm, respec-
tively. LI, VI, and PI was evident in 76 (15.1%), 92
(18.3%), and 56 (11.2%) patients, respectively, and the
lymph nodes were involved in 38 (7.8%).
The receiver operating characteristic area under the curve
values of thewhole and solid tumor sizes used for predicting
LI, VI, PI, pathologic high-grademalignancy (LI, VI, or PI),
and lymph node metastasis are given in Table 2 and
Figure 2. The predictability of all outcomes on the basis
of solid tumor size was better than that using the whole tu-
mor size for all subjects.
Although a significant relationship was noted between
the whole tumor size and maxSUV (decision coefficient,
r2¼ 0.015; P¼ .007), a much more significant relationship
was detected between the solid tumor size and maxSUV
(r2 ¼ 0.211, P<.001).
The possible predictors of pathologic high-grade malig-
nancy (LI, VI, or PI) were also investigated (Table 3). Al-
though whole tumor size, solid tumor size, and maxSUV
were all significant determinants on the univariate analyses,
the solid tumor size and maxSUV were significant determi-
nants on multivariate analysis. Whole tumor size was not an
independent predictor of high-grade malignancy.ery c March 2012
FIGURE 1. Examples of whole and solid tumor sizes on high-resolution computed tomography. A, Whole tumor size, 1.5 cm and solid tumor size, 1.5 cm.
B, Whole tumor size, 2.8 cm and solid tumor size, 1.0 cm. C, Whole tumor size, 3.0 cm and solid tumor size, 0 cm.
TABLE 1. Patient characteristics
Variable n ¼ 502
Age (y) 65.3  9.6
Gender
Male 223 (44.4)
Female 279 (55.6)
Tumor size
Whole (cm) 1.97  0.59
Solid (cm) 1.20  0.88
MaxSUV 2.84  3.03
Procedure
Lobectomy 320 (63.7)
Limited (wedge plus segmentectomy) 182 (36.3)
Lymphatic invasion
Negative 426 (84.9)
Positive 76 (15.1)
Vascular invasion
Negative 410 (81.7)
Positive 92 (18.3)
Pleural invasion
Negative 446 (88.8)
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SNo significant difference in DFS was identified between
patients with a whole tumor size of 2.0 cm or less (n¼ 289;
3-year DFS rate, 92.5%) and those with a whole tumor size
greater than 2.0 cm (n ¼ 213; 3-year DFS rate, 86.7%;
P ¼ .511; Figure 3, A). In contrast, a significant difference
in DFS was identified between patients with a solid tumor
size of 2.0 cm or less (n ¼ 400; 3-year DFS rate, 93.2%)
and those with a solid tumor size greater than 2.0 cm
(n ¼ 102; 3-year DFS rate, 78.9%; P ¼ .013; Figure 3, B).
Univariate analysis of DFS among the 502 patients with
adenocarcinoma included preoperative tumor factors
(eg, whole tumor size, solid tumor size, and maxSUV;
Table 4) as variables. A larger solid tumor size and greater
maxSUVwere associated with a shorter DFS, but the whole
tumor size was not associated with DFS. Moreover, the
multivariate analysis that included a solid tumor size and
maxSUV as variables demonstrated that solid tumor size
(hazard ratio [HR], 2.30; 95% confidence interval [CI],
1.46–3.63; P< .001) and maxSUV (HR, 1.08; 95% CI,
1.00–1.17; P ¼ 0.05) were independent prognostic factors
for DFS (Table 4).
In another multivariate analysis, including the variables
of gender, operation type, solid tumor size, maxSUV, and
lymph node metastasis, the solid tumor size (HR, 2.00;
95% CI, 1.19–3.36; P ¼ .009), maxSUV (HR, 1.10; 95%
CI, 1.01–1.20; P ¼ .034), and lymph node metastasis
(HR, 7.17; 95% CI, 3.18–16.2; P<.001) were independent
prognostic factors for DFS. In contrast, the whole tumor
size was not an independent factor for DFS. However, max-
SUV and lymph node metastasis were significant in the
model replacing solid tumor size with whole tumor size.Positive 56 (11.2)
Lymph node metastasis
Negative 464 (92.4)
Positive 38 (7.6)
Data in parentheses are percentages. maxSUV,Maximum standardized uptake value.DISCUSSION
The frequency of identification of small lung cancers has
increased since CT and enhanced scanning have becomeThe Journal of Thoracic and Caroutine procedures. Such small tumors, especially in lung ad-
enocarcinomas, often contain GGO components as visual-
ized on HRCT.1-4,10 Generally, clinical physicians measure
the tumor size according to the TNM classification by
including the GGO components visualized on HRCT.
On the basis of our hypothesis that the solid components,
and not the GGO components, of tumors as visualized on
HRCT indicate malignancy and prognosis, we evaluated
the role of solid tumor size (the size without the GGO com-
ponent) in cases of clinical stage IA lung adenocarcinomardiovascular Surgery c Volume 143, Number 3 609
TABLE 2. Receiver operative characteristic area under the curve values of whole and solid tumor sizes used to predict pathologic findings
Variable
Whole tumor size Solid tumor size
AUC (95% CI) P value AUC (95% CI) P value
LI 0.560 (0.494–0.626) .092 0.777 (0.733–0.820) <.001
VI 0.634 (0.571–0.697) .001 0.829 (0.789–0.868) <.001
PI 0.576 (0.499–0.653) .039 0.771 (0.723–0.820) <.001
LI or VI or PI 0.590 (0.534–0.646) .002 0.829 (0.794–0.864) <.001
N 0.603 (0.519–0.688) .034 0.761 (0.703–0.819) <.001
AUC, Area under the curve; CI, confidence interval; LI, lymphatic invasion; VI, vascular invasion; PI, pleural invasion; N, lymph node metastasis.
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Sand compared its prognostic significance with that of whole
tumor size (the size including the GGO component).
All receiver operating characteristic area under the
curves for predicting LI, VI, PI, high-grade malignancy,
and lymph node metastasis were larger for the solid tumor
size than those for thewhole tumor size. Moreover, the solid
tumor size and maxSUV were identified as independent
predictive factors for high-grade malignancy. These find-
ings indicate that the solid tumor size, and not whole tumor
size, reflects the pathologic findings related to clinical tu-
mor malignancy. Concerning the relationship between tu-
mor size and lymph node metastasis, we should takeFIGURE 2. Receiver operating characteristic area under the curve for detecting
(PI) (D) high-grade malignancy (LI, VI, or PI), and (E) lymph node metastasis
610 The Journal of Thoracic and Cardiovascular Surgaccount of stage migration because 36% of the patients un-
derwent sublobar resection.
The 7th TNM classification for lung cancer divided the
T1 descriptor into T1a (tumors 2 cm) and T1b (tumors
2-3 cm) on the basis of the optimal cutoff point for 5-year
survival.11 We analyzed each DFS point in stage IA adeno-
carcinoma according to the cutoff point of 2 cm using the
whole and solid tumor sizes. Although no significant differ-
ence in DFS was observed between patients with a whole
tumor size of 2.0 cm or less and those with a whole tumor
size of greater than 2.0 cm, a significant difference in
DFS was identified between patients with a solid tumor(A) lymphatic invasion (LI) (B) vascular invasion (VI) (C) pleural invasion
(N) for whole and solid tumor sizes.
ery c March 2012
TABLE 3. Analysis of possible predictors of pathologic high-grade
malignancy (positive for lymphatic, vascular, or pleural invasion)
Variable OR (95% CI) P value
Univariate analysis
Whole tumor size (cm) 1.70 (1.21–2.39) .002
Solid tumor size (cm) 4.86 (3.57–6.63) <.001
MaxSUV 1.51 (1.37–1.66) <.001
Multivariate analysis
Model 1
Whole tumor size (cm) 1.39 (0.94–2.05) .97
MaxSUV 1.49 (1.35–1.64) <.001
Model 2
Solid tumor size (cm) 3.77 (2.69–5.27) <.001
MaxSUV 1.25 (1.14–1.37) <.001
OR, Odds ratio; CI, confidence interval; maxSUV, maximum standardized uptake
value.
FIGURE 3. Disease-free survival (DFS) curves of patients according to
tumor size on high-resolution computed tomography. A, Three-year DFS
rate of 92.5% and 86.7% for a whole tumor size of 2.0 cm or less and
greater than 2.0 cm, respectively (P ¼ .511). B, Three-year DFS rate of
93.2% and 78.9% for solid tumor size of less than 2.0 cm and greater
than 2.0 cm, respectively (P ¼ .013).
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Ssize of 2.0 cm or less and those with a solid tumor size of
greater than 2.0 cm. Furthermore, multivariate Cox analysis
revealed that solid tumor size and maxSUV were indepen-
dent prognostic factors for DFS, and whole tumor size
was not. These results have indicated that the solid tumor
size more closely correlates with survival and the patho-
logic findings than does the whole tumor size.
The present study demonstrated that approximately one
half of the patients with whole tumors greater than 2 cm
could be restaged clinically as having a solid tumor of 2
cm or less. This means that even tumors greater than 2 cm
often contain a GGO component. Currently, phase III ran-
domized trials of standard lobectomy versus experimental
limited resection for small (2 cm in diameter) peripheral
nonsmall-cell lung cancers are ongoing in the United States
(Cancer and Leukemia Group B trial 14053) and Japan (Ja-
pan Clinical Oncology Group trial 0802/West Japan Oncol-
ogy Group trial 4607L). Among patients with lung
adenocarcinomas and a whole tumor size greater than 2.0
cm, 50% have a good prognosis and could be future candi-
dates for limited surgery such as segmentectomy and wedge
resection of the lung if the surgical margin is adequate. No
difference was seen in DFS among patients with a solid tu-
mor size of 2 cm or less, who were treated with lobectomy
versus sublobar resection in the present study (data not
shown); however, this finding should be confirmed by pro-
spective studies.
Several investigators have reported that the prognosis of
patients with lung adenocarcinoma and a large GGO com-
ponent visualized on HRCTwasmuch better than that of pa-
tients with other adenocarcinoma types, irrespective of the
maximal tumor dimension.12-15 In addition, a large
prospective study has examined the specificity, sensitivity,
and accuracy of the radiologic diagnoses of lymphatic/
vessel invasion and nodal involvement of clinical
T1N0M0 adenocarcinoma made according to the HRCT
findings.16 The outcomes failed to corroborate theThe Journal of Thoracic and Capredetermined criteria using the GGO ratio for specificity.
This indicates that using the solid tumor size is much sim-
pler than using the GGO ratio; furthermore, the solid tumor
size can be applied to the T descriptor in the TNM
classification.
In the present study, the maxSUV on FDG-PET/CT was
also a useful factor for predicting pathologic high-grade
malignancy and DFS. We have previously reported on the
usefulness of maxSUVon PET/CT as a predictor of malig-
nancy and the prognosis of adenocarcinoma of the lung but
not for squamous cell carcinoma of the lung.8,9,17,18 In those
reports, the maxSUV was closely related to the occurrence
of LI, VI, PI, and nodal metastasis and was an independent
predictive factor for DFS.8,9,17,18 The interinstitutionalrdiovascular Surgery c Volume 143, Number 3 611
TABLE 4. Univariate and multivariate analyses of disease-free
survival
Variable HR (95% CI) P value
Univariate analysis
Whole tumor size (cm) 1.47 (0.78–2.77) .23
Solid tumor size (cm) 2.49 (1.60–3.89) <.001
MaxSUV 1.10 (1.04–1.17) <.001
Multivariate analysis
Solid tumor size (cm) 2.30 (1.46–3.63) <.001
MaxSUV 1.08 (1.00–1.17) .05
HR, Hazard ratio; maxSUV, maximum standardized uptake value.
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Svariability in the SUVs obtained in the present study was
minimized using an anthropomorphic body phantom.
Therefore, quantitative SUVs adjusted by phantom studies
can be quite dependable, and such correction will help to
overcome a major limitation concerning the wide
variability in SUVs among institutions in multicenter PET
studies.
Generally, FDG uptake is dependent on tumor size,19,20
and the present study demonstrated that solid tumor size
was more closely related to the maxSUV than was the
whole tumor size and that the solid tumor size is
a potential marker of malignancy and prognosis. This
finding is important for lung adenocarcinomas with
a GGO component visualized on HRCT.
CONCLUSIONS
The predictive values of the solid tumor size visualized
on HRCT and the maxSUV on PET/CT for pathologic
high-grade malignancy and prognosis in cases of clinical
stage IA lung adenocarcinoma were greater than those of
whole tumor size. We recommend that the solid tumor
size be used to determine the T descriptor in the TNM clas-
sification of lung cancer and should be defined as the true
tumor size in cases of lung adenocarcinoma with a GGO
component visualized on HRCT.
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